Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.53 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.53 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.53 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.53 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154052 | 0.85 | TGFBR1 (0.52) | TGFBR1CSNK1DCSNK1EMAPK14CSNK1A1 | |
| SCHEMBL4074281 | 0.81 | TGFBR1 (0.34) | TGFBR1CSNK1DCSNK1EMAPK14CSNK1A1 | |
| SCHEMBL4085337 | 0.80 | TGFBR1 (0.34) | TGFBR1CSNK1DCSNK1EMAPK14CSNK1A1 | |
| SCHEMBL28716692 | 0.76 | TGFBR1 (0.68) | TGFBR1CSNK1DCSNK1EMAPK14CSNK1A1 | |
| SCHEMBL3567006 | 0.72 | CHEK2 (0.43) | CHEK2 | |
| SCHEMBL28965492 | 0.71 | TGFBR1 (0.69) | TGFBR1CSNK1DCSNK1EMAPK14CSNK1A1 | |
| SCHEMBL13188586 | 0.71 | TGFBR1 (0.68) | TGFBR1CSNK1DCSNK1EMAPK14CSNK1A1 | |
| SCHEMBL4077862 | 0.70 | TGFBR1 (0.82) | TGFBR1CSNK1DCSNK1EMAPK14CSNK1A1 | |
| SCHEMBL4077858 | 0.70 | TGFBR1 (0.82) | TGFBR1CSNK1DCSNK1EMAPK14CSNK1A1 | |
| SCHEMBL15451326 | 0.70 | BRD4 (0.34) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2784152-B1 | METHODS FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELL | SUMITOMO CHEMICAL CO (JP) | 2019-04-10 | — | — | EP | claimed |
| US-20090099237-A1 | Methods of treating inflammatory diseases | ROCHE PALO ALTO LLC | 2009-04-16 | — | — | US | claimed |
| US-20080146617-A1 | Methods of treating inflammatory diseases | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | claimed |
| EP-1771171-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | Schering-Plough Ltd. (CH) | 2007-04-11 | — | — | EP | claimed |
| WO-2006025988-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | SCHERING-PLOUGH LTD. (CH) | 2006-03-09 | — | — | WO | claimed |
| EP-1169317-B1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | claimed |
| JP-2002541253-A | — | — | 2002-12-03 | — | — | JP | claimed |
| US-6465493-B1 | SUCH AS 4-(4-(4-FLUOROPHENYL)-5-(2-PYRIDYL)-1-HYDROXY-1H-IMIDAZOL-2-YL)BENZONITRILE; ALK5 MEDIATED DISEASES SUCH AS ARTHRITIS, OSTEOPOROSIS, KIDNEY AND RENAL DISEASES, CONGES-TIVE HEART FAILURE, ULCERS, DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | claimed |
| EP-1169317-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2000061576-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-19 | — | — | WO | claimed |
| US-12582677-B2 | Methods for producing retinal tissue and retina-related cell | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2026-03-24 | — | — | US | disclosed |
| EP-3842524-B1 | METHOD FOR PRODUCING CILIARY MARGINAL ZONE-LIKE STRUCTURE | SUMITOMO CHEMICAL CO (JP) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024110758-A2 | NATURAL KILLER CELLS | NK:IO Ltd (GB) | 2024-05-30 | — | — | WO | disclosed |
| US-11724005-B2 | Method for manufacturing ciliary margin stem cells | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-15 | — | — | US | disclosed |
| WO-2023149565-A1 | METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO RETINAL PIGMENT EPITHELIAL CELLS | 国立大学法人大阪大学 | 2023-08-10 | — | — | WO | disclosed |
| WO-2006025988-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | SCHERING-PLOUGH LTD. (CH) | 2006-03-09 | — | — | WO | disclosed |
| EP-1169317-B1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6465493-B1 | SUCH AS 4-(4-(4-FLUOROPHENYL)-5-(2-PYRIDYL)-1-HYDROXY-1H-IMIDAZOL-2-YL)BENZONITRILE; ALK5 MEDIATED DISEASES SUCH AS ARTHRITIS, OSTEOPOROSIS, KIDNEY AND RENAL DISEASES, CONGES-TIVE HEART FAILURE, ULCERS, DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | disclosed |
| EP-1169317-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061576-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099237-A1 | Methods of treating inflammatory diseases | CSNK1A1, PACSIN2, CSNK1G1 | TGFBR1 3096/4885CSNK1D 16/4885CSNK1E 5/4885 |
| US-20080146617-A1 | Methods of treating inflammatory diseases | CSNK1A1, PACSIN2, CSNK1G1 | TGFBR1 3096/4885CSNK1D 16/4885CSNK1E 5/4885 |
| US-12582677-B2 | Methods for producing retinal tissue and retina-related cell | CNTN1, WNT3A, MYH10 | TGFBR1 1942/4885CSNK1D 268/4885CSNK1E 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.